Premium
Toxicological study of β—HPC and innovative potential drug for metabolic syndrome
Author(s) -
MendozaRivera Brissa,
ReyesEsparza Jorge,
De la CruzCodero Ricardo,
RodriguezFragoso Lourdes
Publication year - 2015
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.29.1_supplement.1023.3
Subject(s) - drug , metabolic syndrome , medicine , carnitine , body weight , kidney , pharmacology , endocrinology , physiology , obesity
β‐hydroxyphospho‐carnitine (β—HPC) has a pharmacological activity to decrease serum glucose, cholesterol and triglycerides, as well as, it is able to reduce body weight in obese rats. Then, these effects make to β—HPC a suitable drug for treating metabolic syndrome (MS). However, no data about its safety are available. Therefore, this study was focused to evaluate the toxicological effects of the β—HPC after a chronic administration. For the study we used male Wistar rats 120 gr. The experimental animals were divided into two groups of, a control group and other group receiving β—HPC (100 mg/kg) by oral gavage for 24 weeks. The results showed that there were no significant changes in body weight, bone marrow cell cycle, blood count parameters, blood chemistry, kidney and liver function in the control group and the group treated with the β—HPC. Furthermore, no morphological changes were observed in the structure of the different tissues analyzed. In conclusion, β‐HPC has not significant toxic effects. β—HPC could therefore be potentially used in the treatment of metabolic syndrome.